MiR-506 exerts antineoplastic effects on osteosarcoma cells via inhibition of the Skp2 oncoprotein

S-phase kinase-associated protein 2 (Skp2) performs oncogenic features in cancers; nonetheless, how Skp2 is regulated posttranscriptionally is elusive in osteosarcoma. Due to this fact, we